54 results about "Nasal Drops" patented technology

The invention relates to application of visceral odorobacter and outer membrane vesicles thereof in preparation of drugs for treating acute lung injury, and relates to the technical field of drugs. The modeling medicine lipopolysaccharide is applied to a mouse individual in a nasal dripping mode, the administration mode is that each mouse is administered once a day, and intragastric administration is carried out once a day after modeling is carried out for two days and lasts for 7 days. Experiments prove that visceral odorobacter and outer membrane vesicles of the visceral odorobacter reduce the number of M1 type alveolar macrophages by down-regulating proinflammatory factors IL-6, TNF-alpha and IL-1beta in lung tissues and inhibiting three proinflammatory factors IL-6, TNF-alpha and IL-1beta in serum, so that the effect of remarkably reversing acute lung injury is achieved. The visceral odor bacilli and the outer membrane vesicles thereof are used for preventing and treating the acute lung injury, and a new method and means are provided for clinically treating the acute lung injury.

The invention discloses a construction and evaluation method of a PM2.5 induced chronic obstructive pulmonary disease acute exacerbation mouse model, and relates to the technical field of disease animal models. The invention aims to evaluate whether PM2.5 can induce acute exacerbation of COPD through a mouse model, a COPD model is established by adopting combined treatment of smoking and lipopolysaccharide (LPS), and an infectious AECOPD model is established by using common klebsiella pneumoniae (KP) nasal drop on the basis. Meanwhile, PM2.5 processing is added on the basis of the COPD model, and the effect of PM2.5 on acute exacerbation of COPD is evaluated. Through comparison with a classical model (an infectious AECOPD model), the potential effect of PM2.5 in induction of acute exacerbation of COPD is evaluated, and an important reference is provided for future research on an AECOPD animal model induced by air pollution.

The present invention relates to the technical field of nanomaterials for vaccines, and particularly relates to a sepiolite in-situ grown nanozyme, a preparation method thereof and an application thereof. The preparation method is to mix ferric chloride, ethylene glycol and sodium acetate to form a suspension, and then mix sepiolite with the suspension, and react at a temperature of 180-200 °C to obtain a black precipitate. After washing and drying, sepiolite in-situ grown nanozyme is obtained. The sepiolite nanozyme realizes the in-situ growth of iron-based nanozyme on the surface of sepiolite rod-like nanostructures under hydrothermal conditions, significantly enhancing the peroxidase activity. After Sep@IONzyme is connected with inactivated influenza virus, the complex forms an appropriate positive charge distribution, enhancing the adhesion ability of the antigen to nasal mucosa. Immunizing mice with it as a nasal drop vaccine significantly improves the levels of respiratory mucosal specific sIgA antibody and serum specific IgG antibody, and can completely protect against the lethal attack of influenza virus.

The utility model relates to the technical field of medical instruments, and discloses a nasal cavity drug delivery device which comprises a conical transfer cylinder, the side wall of one end of the transfer cylinder can be attached to the inner wall of the front end of a nostril, the other end of the transfer cylinder can be located in the nostril, the end, located in the nostril, of the transfer cylinder is defined by a plurality of petal-shaped connecting pieces, and the other end of the transfer cylinder is attached to the inner wall of the front end of the nostril. A dripping nozzle on the nose drop penetrates through the adapter cylinder to open the connecting piece and is located in the nostril, the connecting piece, the adapter cylinder, the dripping nozzle and the nostril are matched to seal the front end of the nostril, an annular supporting part used for supporting the nose drop is arranged at the end, away from the connecting piece, of the adapter cylinder, the supporting part is located at the nostril and the middle of a person, the longitudinal section of the supporting part is arched, and the supporting part is elastic. The end, away from the connecting piece, of the supporting part is provided with an adhesive part capable of being attached to the nose wing and the human middle, and the longitudinal section of the end, located in the nostril, of the transfer cylinder is arc-shaped. According to the utility model, liquid medicine can be prevented from flowing out of nostrils, and effective administration is ensured.

The invention discloses application of a TGM2 inhibitor in treatment of chronic sinusitis with nasal polyp, asthma and fibrosis complications thereof. Through single cell transcriptome analysis, it is found that the TGM2 is specifically and highly expressed in a macrophage subset (Tgm < 2 + > macrophage) in a CRSwNP sample with asthma, and the TGM2 protein expression level is significantly and positively correlated with the clinical severity of diseases such as CRSwNP and asthma; animal experiments verify that pathological injuries of the nasal cavity and the lung of a Tgm2-knocked-out mouse type 2 inflammation model are relieved, the inflammation of the upper and lower respiratory tracts of the mouse and the fibrosis level of the lung tissue can be remarkably relieved by adopting a small molecule drug ERW1041E for nasal drop administration, and the safety is good; the invention provides a brand-new treatment strategy for patients with diseases related to type 2 inflammation, and has remarkable clinical transformation value and market prospect.

This invention provides a quality testing method for nasal drops used to treat allergic rhinitis, belonging to the field of pharmaceutical testing. Specifically, it includes the following steps: S1. Preparing a test solution; S2. Preparing a mixed reference solution; S3. Separately sampling the reference solution and the test solution for analysis; S4. Generating a reference fingerprint chromatogram. This invention can present all different types of components of the medicinal materials on a single chromatogram through a single test, allowing for simultaneous determination of multiple components and achieving comprehensive and accurate quality control of Artemisia annua and Scutellaria baicalensis nasal drops. The quality assessment method provided by this invention has optimized chromatographic conditions and undergone methodological validation, possessing the advantages of method stability, good repeatability, and stable and reliable test results.

The invention discloses a nano drug-loaded nasal spray composition for treating nasosinusitis. The nano drug-loaded nasal spray composition is prepared from the following raw materials: nano silver, PVP (Polyvinyl Pyrrolidone), baicalin, flos magnoliae volatile oil, chitosan, PLGA (Poly (Lactic-co-Glycolic Acid), sodium hyaluronate, a citrate buffer solution and the balance of sterile normal saline. The invention also discloses a preparation method of the nano drug-loaded nasal spray composition for treating nasosinusitis, the preparation method comprises the following steps: firstly preparing PVP modified nano silver suspension, then preparing baicalin nanoparticles and magnolia flower volatile oil nanoparticles by adopting an emulsification-solvent evaporation method, and PVP is used as a stabilizer of nano silver to ensure the long-term dispersion stability of nano silver, so that the stability of the nano silver is ensured, and the stability of the nano silver is ensured. Finally, all the components are mixed in a sterile operation table, the pH is adjusted, filtration sterilization is conducted through a 0.22-micron sterile filter membrane, terminal sterilization is conducted through gamma-ray irradiation after split charging is conducted, and the final product can be prepared into quantitative spray or sterile nose drops to meet different clinical requirements.

The invention relates to the technical field of biological medicine, in particular to centipeda minima extracellular vesicle nose drops and a preparation method and application thereof.The centipeda minima extracellular vesicle nose drops comprise active ingredients, plant extracellular vesicles (Cm-EVs) derived from centipeda minima, the concentration of the plant extracellular vesicles (Cm-EVs) is 1 * 10 < 10 >-5 * 10 < 11 > particles / ml; the key active substances are as follows: the content of the Cm-EVs naturally encapsulated sesquiterpene lactone compound centipederin is more than or equal to 50 micrograms per milliliter (detected by HPLC-MS); the pharmaceutical auxiliary materials comprise 0.05 to 0.2 percent (w / v) of sodium hyaluronate, 0.8 to 1.0 percent (w / v) of NaCl and 0.005 to 0.02 percent (v / v) of polysorbate 80; the method has the beneficial effects that the targeted enrichment capability is realized: mucous membrane adhesion is enhanced through surface pectin protein, and the nasal cavity residence time is prolonged to 6 hours (the free medicine is less than 1 hour); the nano-scale particle size (80-200nm) can efficiently penetrate through the mucous layer, and the nasal mucosa drug concentration reaches 20 times of the plasma concentration (rat pharmacokinetic data); the long-acting slow-release property is as follows: the active ingredients are protected by the lipid bilayer, the cumulative release rate of the centipederin within 72 hours reaches 82%, and the free medicine can be completely released within 24 hours.

The application discloses application of a CGRP receptor small molecule antagonist in preparation of a medicine for treating chronic rhinosinusitis with nasal polyps. The medicine preparation is composed of an effective amount of the CGRP receptor small molecule antagonist and pharmaceutically acceptable adjuvants, and the dosage form is a nasal spray / drop / irrigation agent, and the administration route is simple and easy to operate, and is convenient for patients to use. The application can significantly reduce eosinophilic inflammation by inhibiting CGRP-mediated mast cell activation, and has a clear treatment advantage for eosinophilic nasal polyps. Compared with a biological preparation targeting type 2 cytokines, a small molecule compound is safer and simpler to obtain, can significantly reduce the treatment cost of patients, and provides a new efficient and economical choice for nasal polyp treatment.

1. Name of the designed product: medicine packing bottle (purple nose gel nasal drops). 2. Use of the designed product: for packing of purple nose gel nasal drops. 3. Design points of the designed product: in the combination of shape and pattern. 4. Picture or photo best indicating the design points: front view.

The invention relates to the field of allergic rhinitis, and discloses an application of sodium hyaluronate in preparation of an external medicine for treating allergic rhinitis. Based on actual clinical efficacy verification, the mechanism of sodium hyaluronate playing efficacy is that sodium hyaluronate can be used for preparing an external medicine for treating allergic rhinitis; sodium hyaluronate is used for reducing drainage lymph nodes in an atopic individual area and generating specificity I gE by nasal submucosa plasma cells, blocking contact between allergens and the surface specificity I gE of sensitized mast cells or sensitized basophilic granulocytes in a sensitized body, stopping development of anaphylaxis and promoting subduing of nasal mucosa inflammation, so that allergy symptoms are eliminated, and the nasal mucosa inflammation eliminating effect is achieved. According to the embodiment of the invention, the result of treating AR by adopting HA nasal drops shows that an obvious effect is achieved 1-2 days after the medicine is taken, the medicine takes effect quickly, the safety is relatively high, and the medicine can be used as a new product for industrial reproducible production.

The present invention discloses a broad-spectrum influenza vaccine antigen fragment, recombinant probiotics and applications. The present invention utilizes the high conservation of the M2e sequence in different subtypes of influenza viruses and is expected to develop into a broad-spectrum influenza vaccine with cross-protection efficacy. The probiotic Escherichia coli EcN is used to express and secrete the 5M2e antigen. The vaccine preparation process does not involve live viruses. Compared with the traditional chicken embryo influenza vaccine preparation method, the operation is safer and simpler, and it is suitable for rapid large-scale production. The vaccine of the present invention can be immunized by nasal drops. Compared with the commonly used intramuscular injection immunization route, it is safer and simpler to use, and is closer to the natural invasion route of influenza viruses into the host, which is conducive to inducing mucosal immune responses.

The utility model discloses a mouse nasal drop device which comprises a tube body and a liquid storage tube installed on the tube body. A dripping opening is formed in one end of the tube body, a supporting table is arranged in the tube body, and a through hole is further formed in the supporting table; one end of the liquid storage pipe is attached to the supporting table through an arranged sealing gasket, a liquid outlet hole is formed in the sealing gasket, and the sealing gasket is communicated with the through hole through the liquid outlet hole so that liquid in the liquid storage pipe can flow to the dripping opening. On the basis, the required dosage of nasal drop reagent is injected into the liquid storage tube and then dripped into the nasal cavity of the mouse through the dripping opening, so that compared with a pipette, the device has the advantages of convenience in operation and rapidness and convenience in liquid dripping, particularly, the dripping liquid is quantitatively measured, and the dripping opening is inserted into the nasal cavity, so that the nasal drop reagent is more convenient to use. Therefore, the problem that the test result is interfered by insufficient dropping liquid and outflow of the dropping liquid can be effectively solved.

The invention discloses a method for constructing a Yunnan pine pollen allergy animal model, which belongs to the technical field of Yunnan pine pollen allergy prevention and treatment and comprises the following steps: preparing Yunnan pine pollen allergens and sensitizing non-human mammals. The sensitization treatment comprises a basic sensitization treatment stage and an excitation sensitization treatment stage: in the basic sensitization treatment stage, peritoneal sensitization is carried out once a week and is continued for four weeks; in the nasal-drop sensitization treatment stage, different test substances with the concentration 2 times that of the basic sensitization stage are used for continuous 7-day quantitative nasal-drop excitation, and the nasal drop dosage is 2 microliters / g, and the symptoms of the mouse are observed within 10 minutes after nasal-drop excitation is completed each time. The allergic animal model constructed by adopting the crude extract of the pinus yunnanensis pollen allergen is the first animal model research related to pinus yunnanensis allergy at present, and a reference basis can be provided for subsequent experimental research on the aspect of deep research on pinus yunnanensis pollen allergy; a research model is provided for clinical research on the Yunnan pine pollen allergy or screening of medicines for resisting the Yunnan pine pollen allergy.

The invention discloses application of arginine vasopressin in treatment of slow transit constipation, and relates to the technical field of medicines for treating slow transit constipation. The arginine vasopressin nose drop is found to have a very good treatment effect on slow transit constipation for the first time, and especially for loperamide-induced slow transit constipation, the arginine vasopressin nose drop can effectively promote intestinal tract movement and improve constipation symptoms. The arginine vasopressin is prepared into nose drops, can bypass a blood brain barrier to enter the brain, directly targets downstream nuclei of AVP neurons in a hypothalamic para-ventricular nucleus PVN nuclei, and intervenes treatment in the nerve center, and the effect is better. The discovery of the invention expands a new application for arginine vasopressin drugs, and also provides a new idea for development of constipation drugs.

The utility model discloses a medical nasal scab trimmer, which belongs to the technical field of medical instruments and comprises a holding rod, a switch arranged on the front side of the holding rod, a button arranged on the side wall of the holding rod, a connecting seat detachably connected to the top of the holding rod, a mounting rod detachably connected to the top of the connecting seat, and a protective cover inserted into the top of the holding rod. The connecting base and the mounting rod are located in the protective cover, and trimming mechanisms are arranged in the connecting base and the mounting rod. The device has the beneficial effects that the auxiliary mechanism is arranged and comprises the storage box, nasal drops are stored in the storage box, and before trimming, a proper amount of nasal drops are sprayed to the nasal cavity through the auxiliary mechanism to soften nasal scab, so that trimming is facilitated; the spotlight is arranged, so that the nasal mucosa condition can be observed conveniently; the liquid outlet pipe and the connecting pipe are in threaded connection, the connecting base is convenient to disassemble, meanwhile, the clamping base is arranged, after the liquid outlet pipe and the connecting pipe are separated, the end of the liquid outlet pipe is inserted into the clamping base, and the situation that nasal drops remaining in the liquid outlet pipe flow to the storage battery, and danger is caused is avoided.

The invention relates to aqueous solutions containing a combination of lactoferrin with lactoperoxidase or with povidone iodine, encapsulated in liposomes, as active ingredients together with other components for use as nasal drops and nebulizers in combination with a mouth and face spray with antiviral, antiseptic and anti-inflammatory effects.

The invention discloses a mouse BHDS pulmonary focal degenerative pulmonary bullous model construction method and application, and the method comprises the following steps: adaptively feeding a healthy mouse for one week, then carrying out HCl injury treatment, and giving two microRNA fitting substances to the mouse twice in a nasal drop mode to obtain the BHDS pulmonary focal degenerative pulmonary bullous model. Expression changes of characteristic molecules in BHDS clinical sample lung tissues exist in the lung tissues of the model constructed by the invention, and the model is most suitable for BHDS-like lung tissue pathology so far. The invention provides a proper tool model for the effectiveness, safety and drug screening of BHDS pulmonary focal degenerative pulmonary bullous (BHD syndrome pulmonary cystic disease) treatment drugs, and ensures the repeatability and high efficiency of the model. Compared with a model constructed by gene knockout, the construction method provided by the invention is more stable in model formation, simpler and more convenient in operation method and experimental technology, and lower in cost.

The invention provides a nasal drug delivery three-stage recursion type targeting hydrogel microsphere as well as a preparation method and application thereof, and belongs to the technical field of drug delivery. The invention develops a three-stage recursive targeting nasal drop, and the first-stage nasal mucosa targeting is realized by non-invasive drug delivery into the brain through the charge modified hydrogel microsphere nasal cavity; a targeting liposome carrying CTLA-4 is combined with the activated microglial cells, so that second-stage cell targeting is realized; mitochondrial regulation and control are carried out by releasing DHEA to complete three-stage targeting, and finally, multi-stage precise targeting and intracerebral regulation and control are realized. The three-stage recursion type targeted nasal drops can break through the complex physiological and pathological microenvironment of a brain body layer by layer to directly reach lesion core mitochondria of microglia cells, the Drp-1 pathway is regulated and controlled through DHEA, the abnormal mitochondrial division is remarkably inhibited, the mitochondrial morphological function is stabilized, microglia cell activation is inhibited, and cognitive impairment caused by anesthesia operation is relieved. In conclusion, the research provides a new method for treating various central nervous system diseases.

The present invention belongs to the technical field of cancer immunotherapy and specifically relates to a combination-therapy drug and composition of a cholesterolylated TLR7 liposome and a TLR9 agonist and use thereof. Toll-like receptor agonists have poor targeting capability and significant side effects in anti-tumor treatment, and, as monotherapy in anti-tumor treatment, have limited efficacy. To address the described issues, the present invention provides the cholesterolylated TLR7 liposome, which is prepared from the cholesterol-modified 1V209 molecule 1V209-Cho, a lipid component, and cholesterol, and uses the liposome in combination with the TLR9 agonist to treat tumors. Animal results show that the combination of the liposome and the TLR9 agonist, when administered as nasal drops or by means of intramuscular injection, can significantly inhibit pulmonary metastasis of cervical cancer cells and melanoma cells, indicating that using the cholesterolylated liposome 1V209-Cho-Lip in combination with the TLR9 agonist to treat tumors is a strategy with great potential.

The utility model discloses a nasal cavity medicine dripping body position fixing pillow which comprises a supporting and fixing assembly, the upper end of the supporting and fixing assembly is provided with an abutting pillow assembly, a height adjusting assembly for adjusting the height of the abutting pillow assembly is installed in the abutting pillow assembly, and the height adjusting assembly is connected with a limiting and fixing assembly. By adding the design of the supporting and fixing assembly and fixing the abutting pillow assembly and the height adjusting assembly on the supporting plate, when a patient needs to drip medicine in a nasal cavity in different places, the abutting pillow assembly and the height adjusting assembly can be moved to different positions to be used by moving the supporting and fixing assembly; when the abutting pillow assembly needs to be fixed, the storage cover is opened, the suction cups are sucked to a nursing bed, and then the device can be fixed and used, so that the device can be conveniently moved and used at any time, use is flexible, operation is convenient, and the practicability of the device is improved.

This invention provides a PND cyclodextrin inclusion complex, its preparation method, and its applications, relating to the field of pharmaceutical formulation technology. The method for preparing the PND cyclodextrin inclusion complex of this invention does not use organic solvents, is simple and easy to control, and has low cost. The technical solution of this invention greatly improves the solubility of PND in water, enhances the therapeutic effect of PND, and improves the stability of PND. This inclusion complex is suitable for preparing clinically required solid and liquid dosage forms, including infusions, injections, powder injections, oral solutions, novel nasal drops, nasal sprays, syrups, tablets, capsules, granules, and dispersible tablets. This inclusion complex can be used to prepare drugs for the prevention and treatment of influenza A virus infection.

The invention discloses an akabane virus challenge animal model and an establishment method and application thereof, and belongs to the technical field of animal models.According to the establishment method, a BALB / c mouse or a C57BL / 6N mouse is challenged in a nasal drop mode, so that an akabane virus challenge BALB / c mouse model or an akabane virus challenge C57BL / 6N mouse model is obtained, akabane virus liquid is adopted in the nasal drop mode, and the akabane virus liquid is adopted in the nasal drop mode. The akabane virus liquid is obtained from akabane viruses in an in-vitro cell culture mode, and the akabane virus strains are preferably GXLCH 16-70 strains; the akabane virus counteracting animal model constructed by adopting the method disclosed by the invention expands the universality of the akabane virus counteracting model on the week age and strain of the mouse, and is particularly applicable to model construction of the mouse with mature immune system; the obtained model has great application prospects in evaluating the effectiveness of akabane virus vaccines, screening akabane disease prevention drugs or screening akabane disease treatment drugs.

This invention relates to the field of plant-derived extracellular vesicles, and discloses a method for preparing and applying Hypericum perforatum-derived exosome-like nanovesicles (HPDENs). This invention prepares HPDENs with natural vesicle structures through a specific process, utilizing the natural characteristics of plant-derived vesicles to encapsulate Hypericum perforatum (…). HP The active ingredient, combined with nasal drops, achieves targeted delivery to the brain. It exerts its antidepressant effect by regulating microglia polarization imbalance and reshaping the "neuroimmune-synaptic" axis. This solves the core problems of traditional antidepressants, such as slow onset of action, poor treatment response, and large side effects. It can also improve the core pathological features of depression (neuritis, synaptic plasticity damage) and improve depressive-like behaviors, providing a brand-new option for the clinical treatment of depression.

This invention relates to an engineered mesenchymal stem cell exosome complex, comprising mesenchymal stem cell exosomes and siRNA loaded on the mesenchymal stem cell exosomes. The invention also relates to a nasal drop formulation comprising the aforementioned exosome complex, which can be used to prepare a drug for treating bronchopulmonary dysplasia. The complex and formulation of the present invention possess unique advantages such as enhanced therapeutic specificity through targeted gene silencing, stable pulmonary vascular pathological repair effects, and engineered targeted therapy.

The invention relates to the technical field of medicines, and relates to application of carvedilol in preparation of a novel coronavirus respiratory mucosa vaccine. The novel coronavirus respiratory mucosa vaccine is a vaccine which takes carvedilol as a unique immunologic adjuvant or a composite adjuvant containing capsaicin and is inoculated through a nasal drop or nasal spray way to prevent novel coronavirus infection. The recombinant new coronavirus spike protein is used as an antigen and is mixed with carvedilol, and the mixture is inoculated to a narla golden hamster in a nasal drop manner. Experimental results show that carvedilol can effectively promote a body to generate a specific antibody aiming at spike protein, so that the IgG level in serum is remarkably improved, and IgA response in alveolar lavage fluid is also enhanced. Therefore, a basis is provided for development of carvedilol as a respiratory mucosa vaccine adjuvant.

The present disclosure relates to a C-based single domain antibody that neutralizes respiratory syncytial virus (RSV) and its application thereof. The C-based single domain antibody of the present disclosure is a neutralizing antibody against RSV F protein, can inhibit the viral entry into host cells, and can be used for the prevention, treatment and diagnosis of RSV, as well as for further studying the mechanism of RSV infection. The C-based single domain antibody has a smaller molecular weight, better tissue permeability and the ability to bind to antigenic epitope with steric hindrance effect; it can be expressed in multiple expression systems, including prokaryotic, yeast, and mammalian cells. The C-based single domain antibody has a low production cost and a short production cycle; it has a wide range of administration routes and can be administered through nasal drops, nasal spray, spray, aerosol inhalation, intramuscular injection, intravenous injection, subcutaneous injection, etc.

The present application relates to the technical field of traditional Chinese medicine. The purpose is to provide a traditional Chinese medicine hot compress for treating children's rhinitis, which comprises the following weight parts of traditional Chinese medicine raw materials: perilla seed 4-6 parts, radish seed 4-6 parts, white mustard seed 2-4 parts, xanthium 2-4 parts, cyperus 2-4 parts, asarum 1-2 parts, evodia 1-2 parts. The present application uses external application of medicine, the use mode is simple, and the patient compliance is high. Through precise proportioning of the prescription, the special prescription is suitable for special diseases, the force is special and one, and the chronic rhinitis patients can take the medicine for a long time, which is convenient, safe and reliable in curative effect. As a pure traditional Chinese medicine formula, its preparation and use are safer and more reliable than furazolidone and other hormone nasal drops in the treatment of rhinitis, and are green and safe.

The invention discloses an application of a CGRP receptor small molecule antagonist in preparation of a medicine for treating eosinophilic chronic sinusitis with nasal polyp. The pharmaceutical preparation is composed of an effective amount of a CGRP receptor small molecule antagonist and pharmaceutically acceptable auxiliary materials, the dosage form is nasal spray / nose drop / irrigation, and the pharmaceutical preparation is simple and convenient in administration route, easy to operate and convenient for patients to use. According to the invention, by inhibiting CGRP-mediated mast cell activation, eosinophilic granulocyte inflammation is significantly relieved, and especially, the traditional Chinese medicine composition has a definite treatment advantage on eosinophilic granulocyte nasal polyp; and compared with a biological agent of a targeted type 2 cytokine, the small molecule compound is safer, simpler and more convenient to obtain, the treatment cost of a patient can be remarkably reduced, and a new efficient and economic choice is provided for nasal polyp treatment.

The invention relates to a Zn-Mn bimetallic ZIF material for RNA delivery and a preparation method and application of the Zn-Mn bimetallic ZIF material. The Zn-Mn bimetallic ZIF material disclosed by the invention has natural immunity and mucosal immunity activation capability, can play a role in preventing and / or treating respiratory virus infection in a manner such as nasal drip immunity, can efficiently load RNA, has excellent cell membrane penetration performance and controllable RNA release characteristic as an RNA carrier, and can be applied to preparation of a medicine for treating respiratory virus infection. Non-targeted delivery of RNA molecules can be realized through different administration modes such as intraperitoneal injection, nasal dripping and pulmonary delivery. Therefore, the Zn-Mn bimetallic ZIF material disclosed by the invention has a wide application prospect in the fields of respiratory virus prevention and treatment, gene therapy drugs, vaccine development and the like.